Innovation Fund Invests in New Project to Advance Clinical Research
It should be easier for Danes to sign up for and participate in clinical trials. An investment of DKK 15.6 million DKK from the Innovation Fund launches a national project to move clinical research closer to the citizens. It is a number of health Denmark's heaviest and most knowledgeable actors that are behind a strong public-private partnership.
Project to contribute in three ways:
- The implementation of a National Experimental Overview. A platform that can give citizens an overview of clinical trials in Denmark, as well as where they can turn to to find out more.
- The implementation of a Digital Recruitment Platform that is under development. A platform where access to health data creates better conditions for contact between trial participants and those responsible for clinical trials.
- Strengthened framework for patient-centered decentralized clinical trials.
Read more about this investment here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
